The estimated Net Worth of Edward C Albini is at least $506 Mille dollars as of 5 March 2024. Mr. Albini owns over 8,750 units of Sutro Biopharma Inc stock worth over $506,376 and over the last 6 years he sold STRO stock worth over $0. In addition, he makes $0 as Chief Financial Officer at Sutro Biopharma Inc.
Sign up
Mr. Albini STRO stock SEC Form 4 insiders trading
Edward has made over 13 trades of the Sutro Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 8,750 units of STRO stock worth $40,338 on 5 March 2024.
The largest trade he's ever made was exercising 45,698 units of Sutro Biopharma Inc stock on 13 February 2023 worth over $265,505. On average, Edward trades about 7,811 units every 90 days since 2018. As of 5 March 2024 he still owns at least 109,843 units of Sutro Biopharma Inc stock.
You can see the complete history of Mr. Albini stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Albini biography
Edward Albini is Chief Financial Officer of the Company. During 2012, Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016, Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant (inactive status) in California.
How old is Edward Albini?
Edward Albini is 62, he's been the Chief Financial Officer of Sutro Biopharma Inc since 2013. There are 11 older and 6 younger executives at Sutro Biopharma Inc. The oldest executive at Sutro Biopharma Inc is Dr. Shabbir T. Anik, 68, who is the Chief Technical Operations Officer.
What's Edward Albini's mailing address?
Edward's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Sutro Biopharma Inc
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund e Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
What does Sutro Biopharma Inc do?
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
What does Sutro Biopharma Inc's logo look like?
Complete history of Mr. Albini stock trades at Sutro Biopharma Inc
Sutro Biopharma Inc executives and stock owners
Sutro Biopharma Inc executives and other stock owners filed with the SEC include:
-
William Newell,
Chief Executive Officer, Director -
William J. Newell J.D.,
CEO & Director -
Trevor Hallam,
Chief Scientific Officer -
Arturo Molina,
Chief Medical Officer -
William J. Newell,
CEO & Director -
Jane Chung R.Ph.,
Chief Commercial Officer -
Dr. Trevor J. Hallam,
Pres of Research & Chief Scientific Officer -
Linda A. Fitzpatrick,
Chief People & Communications Officer -
Connie Matsui,
Chairman of the Board -
Shalini Sharp,
Independent Director -
Joseph Lobacki,
Independent Director -
Michael Dybbs,
Independent Director -
John Freund,
Independent Director -
Daniel Petree,
Director -
Annie Chang,
Head of Investor Relations -
Diana Landa,
Vice President of Regulatory Affairs -
James Panek,
Director -
Shabbir Anik,
Chief Technical Operations Officer -
Brunilda Shtylla,
Vice President - Business Development -
Craig Berman,
Vice President - Clinical Development -
Kristin Bedard,
Vice President - Immunobiology -
Carlos Lugo,
Vice President - Quality and CMC Regulatory Operations -
Regina Cheng,
Vice President - Finance, Controller -
Linda Fitzpatrick,
Chief People and Communications Officer -
Edward Albini,
Chief Financial Officer -
Dr. James R. Swartz Ph.D., Sc.D.,
Founder -
Dr. Arturo M. Molina FACP, M.D., MS,
Chief Medical Officer -
Annie J. Chang M.B.A.,
VP of Investor Relations -
Dr. Arturo M. Molina,
Chief Medical Officer -
Dr. Nicki Vasquez Ph.D.,
Chief Portfolio Strategy & Alliance Officer -
David Pauling J.D., M.A.,
Gen. Counsel -
Dr. Shabbir T. Anik,
Chief Technical Operations Officer -
Edward C. Albini,
CFO & Sec. -
Dr. James R. Swartz,
Founder and Member of Scientific Advisory Board -
Nicki Vasquez,
CHIEF PORT. STRAT & ALNCE OFCR -
Corp /De/ Celgene,
-
Michael Jay Ross,
Director -
Partners Viii, L.P.Alta Par...,
-
V Bryan Lawlis,
Director -
Daniel Janney,
Director -
Stephen Worsley,
Chief Business Officer -
& Co., Inc.Merck Sharp & Do...,
-
Venture Partners V Lp Skyli...,
-
V, Llcilsf Iii, Llcinternat...,
-
Jane Chung,
PRESIDENT AND COO -
Venkatesh Srinivasan,
CHIEF TECH OP OFFICER -
Anne Elizabeth Borgman,
CHIEF MEDICAL OFFICER -
Sukhi Jagpal,
-
Hans Peter Gerber,
CHIEF SCIENTIFIC OFFICER -
Heidi Hunter,
-
Jon Marc Wigginton,
-
Barbara Leyman,
Chief Business Dev. Officer